Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
12 března, 2021 6:28 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5500 Authors: Takashi Onda, Toyomi Satoh, Toshiaki...
Správa z ASCO 2018 – Gynekologické malignity
12 března, 2021 6:25 pmAj keď sa tohtoročné ASCO nieslo v znamení noviniek a zmien v liečbe pediatrických, pľúcnych, prsníkových a pankreatických karcinómov, boli prezentované niektoré práce z gynekologickej...
Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor- -positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
12 března, 2021 6:20 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer – Metastatic Abstract number: 1005 Authors: Guy Heinrich Maria...
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo-controlled D-CARE study
12 března, 2021 6:13 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 501 Authors: Robert E. Coleman, Dianne Finkelstein,...
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
12 března, 2021 6:11 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 507 Authors: Valentina Guarneri, Maria Vittoria Dieci,...
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease- -free survival (DFS) results
12 března, 2021 6:08 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 506 Authors: Helena Margaret Earl, Louise Hiller,...
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
12 března, 2021 6:06 pmA 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months with chemotherapy, which is currently...
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
12 března, 2021 6:03 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: LBA1 Authors: Joseph A. Sparano, Robert James...
TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy
12 března, 2021 6:01 pmJune 4, 2018 Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive,...
KARCINOM PRSU NA ASCO 2018
12 března, 2021 5:40 pmNejvětší novinky prezentované na posledních konferencích ASCO se zpravidla netýkaly karcinomu prsu, ale jiných solidních nádorů, jako je maligní melanom, karcinom...